BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, Sharifzadeh SO, Soleymani L, Daneshi S, Hushmandi K, Khan H, Kumar AP, Aref AR, Samarghandian S. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother 2021;141:111824. [PMID: 34175815 DOI: 10.1016/j.biopha.2021.111824] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
Number Citing Articles
1 Mirzaei S, Paskeh MDA, Entezari M, Mirmazloomi SR, Hassanpoor A, Aboutalebi M, Rezaei S, Hejazi ES, Kakavand A, Heidari H, Salimimoghadam S, Taheriazam A, Hashemi M, Samarghandian S. SOX2 function in cancers: Association with growth, invasion, stemness and therapy response. Biomedicine & Pharmacotherapy 2022;156:113860. [DOI: 10.1016/j.biopha.2022.113860] [Reference Citation Analysis]
2 Hashemi M, Taheriazam A, Daneii P, Hassanpour A, kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Targeting PI3K/Akt signaling in prostate cancer therapy. J Cell Commun Signal 2022. [DOI: 10.1007/s12079-022-00702-1] [Reference Citation Analysis]
3 Hashemi M, Hajimazdarany S, Mohan CD, Mohammadi M, Rezaei S, Olyaee Y, Goldoost Y, Ghorbani A, Mirmazloomi SR, Gholinia N, Kakavand A, Salimimoghadam S, Ertas YN, Rangappa KS, Taheriazam A, Entezari M. Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106535] [Reference Citation Analysis]
4 Paskeh MDA, Ghadyani F, Hashemi M, Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S, Entezari M, Goharrizi MASB, Salimimoghadam S, Aref AR, Kalbasi A, Rajabi R, Rashidi M, Taheriazam A, Sethi G. Biological function and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: promises and challenges. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106553] [Reference Citation Analysis]
5 Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar H, Heidari H, Salimimoghadam S, Entezari M, Taheriazam A, Hushmandi K. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. Biomedicine & Pharmacotherapy 2022;155:113774. [DOI: 10.1016/j.biopha.2022.113774] [Reference Citation Analysis]
6 Babajani A, Manzari-Tavakoli A, Jamshidi E, Tarasi R, Niknejad H. Anti-cancer effects of human placenta-derived amniotic epithelial stem cells loaded with paclitaxel on cancer cells. Sci Rep 2022;12:18148. [PMID: 36307463 DOI: 10.1038/s41598-022-22562-w] [Reference Citation Analysis]
7 Li J, Kang J, Liu W, Liu J, Pan G, Mao A, Zhang Q, Lu J, Ding J, Li H. Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel <em>via</em> targeting miR-200b-3p/Bcl-2 axis. Eur J Histochem 2022;66. [DOI: 10.4081/ejh.2022.3529] [Reference Citation Analysis]
8 Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, Hashemi M, Tabari T, Rashidi M, Mirzaei S, Zarepour A, Zarrabi A, De Greef D, Bishayee A. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cell Mol Life Sci 2022;79:539. [PMID: 36194371 DOI: 10.1007/s00018-022-04551-4] [Reference Citation Analysis]
9 Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, Goldoost Y, Gholinia N, Kakavand A, Tavakolpournegari A, Salimimoghadam S, Nabavi N, Zarrabi A, Taheriazam A, Entezari M, Hushmandi K. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. International Journal of Biological Macromolecules 2022. [DOI: 10.1016/j.ijbiomac.2022.09.203] [Reference Citation Analysis]
10 Liao W, Li Y, Wang J, Zhao M, Chen N, Zheng Q, Wan L, Mou Y, Tang J, Wang Z. Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy. Int J Nanomedicine 2022;17:4163-93. [PMID: 36134202 DOI: 10.2147/IJN.S380697] [Reference Citation Analysis]
11 Lu W, Yin C, Zhang T, Wu Y, Huang S. An oxidative stress-related prognostic signature for indicating the immune status of oral squamous cell carcinoma and guiding clinical treatment. Front Genet 2022;13:977902. [DOI: 10.3389/fgene.2022.977902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li F, Song Q, Zhang Y, Wang X, Cao L, Li N, Zhao L, Zhang S, Zhuang X. Identifying the EMT-related signature to stratify prognosis and evaluate the tumor microenvironment in lung adenocarcinoma. Front Genet 2022;13:1008416. [DOI: 10.3389/fgene.2022.1008416] [Reference Citation Analysis]
13 Ashrafizadeh M, Hushmandi K, Mirzaei S, Bokaie S, Bigham A, Makvandi P, Rabiee N, Thakur VK, Kumar AP, Sharifi E, Varma RS, Aref AR, Wojnilowicz M, Zarrabi A, Karimi‐maleh H, Voelcker NH, Mostafavi E, Orive G. Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10325] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Liu Z, Fan M, Xuan X, Xia C, Huang G, Ma L. Celastrol inhibits the migration and invasion and enhances the anti-cancer effects of docetaxel in human triple-negative breast cancer cells. Med Oncol 2022;39:189. [PMID: 36071249 DOI: 10.1007/s12032-022-01792-y] [Reference Citation Analysis]
15 Lu J, Fei F, Wu C, Mei J, Xu J, Lu P. ZEB1: Catalyst of immune escape during tumor metastasis. Biomedicine & Pharmacotherapy 2022;153:113490. [DOI: 10.1016/j.biopha.2022.113490] [Reference Citation Analysis]
16 Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother 2022;154:113609. [PMID: 36037786 DOI: 10.1016/j.biopha.2022.113609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wang C, Xu X, Zhang P, Xiong S, Yuan J, Gao X, Guan W, Wang F, Li X, Dou H, Xu G. Lipid-coated albumin-paclitaxel nanoparticles loaded with sorcin-siRNA reverse cancer chemoresistance via restoring intracellular calcium ion homeostasis. J Nanobiotechnology 2022;20:319. [PMID: 35799174 DOI: 10.1186/s12951-022-01487-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. Pharmacol Res 2022;:106311. [PMID: 35716914 DOI: 10.1016/j.phrs.2022.106311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wei M, Ye C, Huang H, Yang C, Zhang L, Huang Y, Wang Y, Luo X, Luo J. Acacetin inhibits the tumor growth of human osteosarcoma cells through regulating Wnt/β-catenin and JNK signaling pathways. Journal of Functional Foods 2022;93:105103. [DOI: 10.1016/j.jff.2022.105103] [Reference Citation Analysis]
20 Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G, Tergaonkar V. NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol 2022. [PMID: 35561232 DOI: 10.1002/jcp.30759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
21 Trinidad-Calderón PA, López-Castillo LM, Gallegos-Martínez S, Trujillo-de Santiago G, García-Lara S, Álvarez MM. nurP28, a New-to-Nature Zein-Derived Peptide, Enhances the Therapeutic Effect of Docetaxel in Breast Cancer Monolayers and Spheroids. Molecules 2022;27:2824. [PMID: 35566175 DOI: 10.3390/molecules27092824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Nasser NJ. Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer. Cancers (Basel) 2022;14:1959. [PMID: 35454866 DOI: 10.3390/cancers14081959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Zhou M, Wen L, Wang C, Lei Q, Li Y, Yi X. Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs. Front Bioeng Biotechnol 2022;10:875034. [DOI: 10.3389/fbioe.2022.875034] [Reference Citation Analysis]
25 Iranmanesh H, Entezari M, Rejali L, Nazemalhosseini-mojarad E, Maghsoudloo M, Aghdaei HA, Zali MR, Hushmandi K, Rabiee N, Makvandi P, Ashrafizadeh M, Hashemi M. The Association of Clinicopathological Characterizations of Colorectal Cancer with Membrane-Bound Mucins genes and LncRNAs. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153883] [Reference Citation Analysis]
26 Deng S, Leong HC, Datta A, Gopal V, Kumar AP, Yap CT. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. Cancers (Basel) 2022;14:1652. [PMID: 35406424 DOI: 10.3390/cancers14071652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
27 Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience 2022;25:103923. [PMID: 35252817 DOI: 10.1016/j.isci.2022.103923] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
28 Speciale A, Muscarà C, Molonia MS, Cristani M, Cimino F, Saija A. Recent Advances in Glycyrrhetinic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy. Molecules 2022;27:1775. [PMID: 35335138 DOI: 10.3390/molecules27061775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Nasser NJ, Sun K, Scanlon KM, Mishra MV, Molitoris JK. Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1-6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare. Cancers (Basel) 2022;14:864. [PMID: 35205611 DOI: 10.3390/cancers14040864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Al-hilfi A, Walker KD. Biocatalysis of precursors to new-generation SB-T-Taxanes effective against Paclitaxel-Resistant cancer cells. Archives of Biochemistry and Biophysics 2022. [DOI: 10.1016/j.abb.2022.109165] [Reference Citation Analysis]
31 Yin Y, Zhang J, Ma T, Chen D, Lu D. miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling. Acta Biochim Biophys Sin (Shanghai) 2022;54:37-46. [PMID: 35130632 DOI: 10.3724/abbs.2021006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Zabolian A, Hashemi M, Hushmandi K, Ashrafizadeh M, Aref AR, Samarghandian S. Cervical cancer progression is regulated by SOX transcription factors: Revealing signaling networks and therapeutic strategies. Biomed Pharmacother 2021;144:112335. [PMID: 34700233 DOI: 10.1016/j.biopha.2021.112335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
33 Roque MC, da Silva CD, Lempek MR, Cassali GD, de Barros ALB, Melo MM, Oliveira MC. Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio. Biomed Pharmacother 2021;144:112307. [PMID: 34653762 DOI: 10.1016/j.biopha.2021.112307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Baldini E, Tuccilli C, Pironi D, Catania A, Tartaglia F, Di Matteo FM, Palumbo P, Arcieri S, Mascagni D, Palazzini G, Tripodi D, Maturo A, Vergine M, Tarroni D, Lori E, Ferent IC, De Vito C, Fallahi P, Antonelli A, Censi S, D'Armiento M, Barollo S, Mian C, Morrone A, D'Andrea V, Sorrenti S, Ulisse S. Expression and Clinical Utility of Transcription Factors Involved in Epithelial-Mesenchymal Transition during Thyroid Cancer Progression. J Clin Med 2021;10:4076. [PMID: 34575184 DOI: 10.3390/jcm10184076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]